FDA expands its approval of Tzield to children as young as one with stage 2 type 1 diabetes, extending the first disease-modifying therapy into an earlier, high-risk population to delay progression to insulin-dependent disease.
FDA expanded the approval of Tzield (teplizumab-mzwv), lowering the eligible patient age from eight years to as young as one year for delaying the onset of stage 3 type 1 diabetes in individuals diagnosed with stage 2 disease.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The decision,
Tzield is a CD3-directed monoclonal antibody designed to modulate the immune response that drives beta cell destruction. Its initial FDA approval in 2022 marked a shift toward earlier intervention in type 1 diabetes, moving beyond glucose control to modifying disease progression. The latest expansion reinforces that strategy, with increasing emphasis on identifying and treating patients before the onset of clinical disease.
“This approval opens an important new chapter in diabetes care for young children with stage 2 type 1 diabetes and their families,” said Kimber Simmons, MD, MS, associate professor of pediatrics at the Barbara Davis Center. “This is especially important because these children are often at the highest risk of progressing quickly and without warning.”
The label expansion is supported by one-year data from the Phase IV Petite-T1D study, evaluating the safety and pharmacokinetics of Tzield in children under eight years of age.2
The trial enrolled 23 participants and assessed a 14-day course of intravenous infusions, with follow-up extending up to 26 months.
Type 1 diabetes is a progressive autoimmune condition in which the immune system destroys insulin-producing beta cells. In stage 2 disease, patients have multiple diabetes-related autoantibodies and abnormal glucose levels but have not yet developed the clinical symptoms associated with stage 3, when insulin dependence begins. Delaying progression to this stage is increasingly viewed as a meaningful clinical endpoint, particularly in pediatric populations where disease management can be more complex.1
“The autoimmune attack driving this disease often begins early in life, and the burden that autoimmune T1D poses in this very young population and their families is significant,” said Christopher Corsico, global head of Development at Sanofi. “This approval underscores the importance of targeting the immune system early in autoimmune type 1 diabetes, aiming to impact its natural progression by delaying the loss of insulin production in the pancreas.”
The approval highlights growing interest in immunomodulatory approaches in diabetes and the broader push toward earlier diagnosis through screening for autoantibodies. It also raises considerations around implementation, including identifying eligible patients at earlier stages and integrating preventive therapies into standard care pathways.
Tzield is already approved in multiple markets, including the European Union, United Kingdom, China, and Canada, for delaying progression to stage 3 disease in patients aged eight years and older with stage 2 type 1 diabetes.
Additional regulatory reviews are ongoing, and the therapy is also under FDA review for a potential new indication in patients recently diagnosed with stage 3 disease.1
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
